OncLive TV

Alexis Ann LeVee, MD, highlights breast cancer abstracts to pay attention to at the 2026 ASCO Annual Meeting.

Premal H. Thaker, MD, MS, discusses the phase 2 MAESTRA 1 trial (NCT07023627) in platinum-resistant ovarian cancer.

Neil D. Gross, MD, FACS, discusses the heterogeneous nature of advanced CSCC.

Tycel Phillips, MD, discusses considerations for navigating treatment options in relapsed/refractory mantle cell lymphoma.

Stephanie A Berg, DO, discusses frequent UTIs in women and when bladder cancer referral may be appropriate.

Sanam Loghavi, MD, discusses the specific updates to the WHO diagnostic criteria in acute myeloid leukemia.

Thomas J. Polascik, MD, discusses findings from a study of an AI-based VOC assay for prostate cancer detection.

Martin W. Schoen, MD, MPH, discusses data from a real-world study of enzalutamide vs apalutamide in mCSPC.

Fred Saad, MD, CQ, FRCS, FCAHS, discusses PSA end point data from the PSMAddition study in PSMA+ mHSPC

Mark D. Tyson, II, MD, MPH, discussed the clinical implications of data from the primary analysis of the PATAPSCO trial in NMIBC.

Joshua J. Meeks, MD, PhD, discusses data from a real-world study of BCG retreatment after BCG failure in NMIBC.

Jason Hafron, MD, discusses findings from a study that evaluated the implementation of a multidisciplinary quality initiative in prostate cancer.

Benjamin Croll, MD, discusses findings from a study of the correlation between radiographic response and pathologic response in RCC.

Mark Garzotto, MD, discusses efficacy data with aglatimagene besadenovec plus valacyclovir and EBRT in localized prostate cancer.

Diana Cirstea, MD, discusses sequencing considerations in relapsed/refractory multiple myeloma in the era of T-cell–redirecting therapies.

Jason Hafron, MD, discusses the significance of the FDA approval of adjuvant atezolizumab for MRD+ muscle-invasive bladder cancer.

Anthony M. Hunter, MD, discusses treatment decision-making for the management of anemia in myelofibrosis.

Colton Jones, MD, shares data from a retrospective analysis of GLP-1 receptor agonists vs aspirin for the primary prevention of colorectal cancer.

Sanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.

Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.

Bruno B. Bockorny, MD, discusses the rationale for evaluating the anti-CCR8 antibody in a phase 1 trial in solid tumors.

Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.

Michael A. Postow, MD, discusses the importance of long-term multidisciplinary follow-up for patients with melanoma treated with ICIs.

Michael A. Postow, MD, discusses the evolving understanding of ICIs in melanoma and the unique toxicity profiles associated with these agents.

Aparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas.

Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.

R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.

R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.

Mario Sznol, MD, discusses current guidance around the use of neoadjuvant therapy in advanced melanoma.

Lore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.